- BTC Health (BTC) investee BioImpact has won exclusive rights to distribute the NEOLA device in Australia, New Zealand and Singapore
- NEOLA is a non-invasive medical device to measure volume changes and oxygen concentration in the lungs of preterm infants
- This allows health care professionals to instantly detect complications and provide the required treatment
- BioImpact secured the rights from GPX Medical AB, which expects to obtain CE approval for NEOLA in 2023
- Pending CE approval, BTC Health will begin the registration process allowing NEOLA to commercially launch in Australia and New Zealand
- BTC Health spiked over 100 per cent earlier today but is now up just 11.25 per cent to trade at 8.9 cents per share
BTC Health: Investee gains NEOLA distribution rights
